ProfileGDS5678 / 1423265_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 88% 84% 88% 84% 86% 84% 84% 83% 84% 84% 84% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2380284
GSM967853U87-EV human glioblastoma xenograft - Control 26.8846788
GSM967854U87-EV human glioblastoma xenograft - Control 36.168384
GSM967855U87-EV human glioblastoma xenograft - Control 47.0077988
GSM967856U87-EV human glioblastoma xenograft - Control 56.218284
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2707786
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1213984
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1701284
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1072883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2341784
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2250684
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2295284
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3296585
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.252884